Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
National Institute for Health and Care Excellence (Nice)
Headquarters: London, United Kingdom
Website: http://www.nice.org.uk
Year Founded: 1999
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jan 13, 2025
Politics, Policy & Law
From PBMs to Biosecure, a conversation with Rep. Auchincloss on The BioCentury Show
The newly minted member of Energy & Commerce has a deep understanding of the biomedical innovation ecosystem
BioCentury | Aug 16, 2023
Regulation
Aug. 15 Quick Takes: April PDUFA for Carvykti in earlier stage MM
Plus: Nucleic acid company Impilo launches to treat solid tumors and updates from Galecto, Design, Arcellx, Amicus, Alaunos, Lidao
BioCentury | Feb 1, 2023
Politics, Policy & Law
House Republicans want to ban QALYs from federal, state healthcare
Patient groups, industry support anti-QALY bill; ICER, consumer groups oppose it
BioCentury | Jan 5, 2023
Politics, Policy & Law
Remembering Michael Rawlins: ‘A terrible beauty’
Rawlins, founding chairman of NICE, chair of MHRA and the U.K. Biobank, dead at 81
BioCentury | Nov 29, 2022
Finance
Regulatory, payer KOLs to inform Gilde investment decisions
Council led by former EMA Executive Director Guido Rasi
BioCentury | Jun 17, 2022
Market Access
U.K. paying for two antibiotics in world first subscription model
NICE’s QALY-based calculation for Zavicefta, Fetcroja goes far beyond simply modeling their health benefits
BioCentury | Sep 2, 2021
Regulation
MHRA seizes opportunity to reshape expedited approval
Newly independent, MHRA leapfrogs FDA, EMA pathways by integrating regulatory, reimbursement throughout the process
BioCentury | Apr 29, 2021
Product Development
NICE joins institute, signaling next step in implementing RWE into cost-effectiveness analysis
NICE is taking the next step in applying real-world evidence to its technology appraisal methodology by joining the GetReal Institute, a public-private partnership that aims to facilitate the adoption
BioCentury | Nov 14, 2020
Politics, Policy & Law
U.K.’s opportunity as changes come to MHRA, NICE
New MHRA pathways and a greater risk tolerance at NICE could make the U.K. an attractive destination for drug developers
BioCentury | Apr 10, 2020
Politics, Policy & Law
Piloting a new course to reimbursing antibiotics
Two European pilots and U.S. legislation aim to revamp the commercial market for antibiotics
Items per page:
1 - 10 of 64